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Muscarinic acetylcholine receptors (mAChRs) belong to a superfamily of G-
protein coupled receptors that are characterized by seven transmembrane spanning
domains. The M2 mAChR subtype plays a key role in regulating cholinergic transmission
in the central and peripheral nervous system. Therefore, analyzing factors that regulate
the expression, function, and trafficking of this receptor is vital. The focus of this study
was to elucidate mechanisms responsible for mediating agonist-induced down-regulation
of the M2 mAChR. To clarify whether down-regulation of the M2 mAChR involved jS-
arrestin, mouse embryonic fibroblasts (MEFs) derived from jS-arrestin knockouts that
lack expression of either one (KOI or K02) or both isoforms (KOl/2) of /3-arrestin 1 and
2 were utilized. Saturation radioligand binding assays were performed with the tritium-
labeled membrane permeable muscarinic antagonist, [ H]-QNB, to examine agonist-
induced down-regulation of FLAG-tagged porcine M2 mAChRs transiently expressed in
MEF KOI, K02 and KOl/2. The data indicates that M2 mAChR down-regulation is /?-
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arrestin dependent. Furthennore, the receptor showed no selectivity between the two jS-
arrestin isoforms in mediating agonist-induced down-regulation. Agonist-induced down-
regulation was both dose and time-dependent in MEF KOI and K02. The M2 mAChR
was maximally down-regulated (30-50 %) six hours following stimulation.
The researcher conducted experiments in Chinese hamster ovary (CHO) cells
stably expressing human M2 mAChRs to determine whether /3-arrestin molecules
undergo ubiquitination as a result of agonist stimulation, hnmunoprecipitation combined
with immunoblot analysis revealed that there was an increase in ubiquitination of
exogenously expressed FLAG-tagged /3-arrestin 2 following agonist stimulation. This
increase in ubiquitination appeared to be maximal after three minutes of agonist
stimulation. Expression of a chimeric form of jS-arrestin 2 that is constitutively mono-
ubiquitinated resulted in down-regulated M2 mAChRs in both stimulated and non-
stimulated cells in MEF KOl/2. These results indicate that agonist-induced down-
regulation ofM2 mAChRs in MEFs is jS-arrestin mediated and that ubiquitination of /3-
arrestin may serve as a sorting signal for receptor down-regulation. Pretreatment with
lactacystin, a proteasomal inhibitor, attenuated agonist-induced down-regulation of M2
mAChRs transiently expressed in MEF KOI, indicating that lactacystin may either block
ubiquitination of /3-arrestin, or inhibit trafficking of the receptor to late endosomes.
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1.0 G-protein coupled receptors and the muscarinic acetylcholine receptor
subfamily
G-protein coupled receptors (GPCRs) comprise a super family of receptors that
are characterized by seven-transmembrane spanning domains, which upon activation by
ligand or agonist, signal through their cognate G-proteins. G-proteins transduce awide
range of extracellular signals across the plasma membrane of the cell into discrete
intracellularmessages capable of regulating numerous and diverse cellular functions.
Over 800 GPCRs are known to date and over 1000 are suspected to be present in the
human genome (Penn et al., 2000). Themajority ofprescribed drugs target either
activation ofGPCRs or their downstream signals (Billington and Penn, 2003). One
subfamily of the GPCRs, the muscarinic acetylcholine receptors (mAChRs), mediates the
actions of the neurotransmitter acetylcholine in the central nervous system and peripheral
nervous system. In mammals, five distinctmAChR subtypes, designated asMl- M5,
have been identified, with each receptor subtype being the product of a separate gene.
The mAChR subtype focused upon in this study, the M2 mAChR, preferentially couples
to pertussis toxin-sensitive Q and Go proteins. Agonist mediated activation of the M2
mAChR results in inhibition of adenylyl cyclase activity (Caufield, 1993).
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1.1 M2 mAChR localization and function
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In the mammalian central nervous system, mRNA encoding theM2 mAChR and
M2-specific immunoreactivity have been localized to basal forebrain/septum, striatum,
hippocampus, hypothalamus, amygdala, and pontine nuclei regions (Caufield, 1993).
The M2 mAChR plays a key role in regulating cholinergic transmission in the
hippocampus and functions as a presynaptic heteroreceptor in modulating the release of
GABA and glutamate (Hajos et al., 1998). Consequently, pathological conditions that
modulate expression and/or function ofM2 mAChR will impair cholinergic transmission
in the hippocampus (Levey, 1996).
The M2 subtype is the main mAChR found in the mammalian heart (Peralta et
al., 1987). Cardiac mAChR activation causes a decrease in both the rate and force of
contraction (Katz, 1992). Furthermore, M2 mAChR mediates agonist-induced
bradycardia, or slowing of the heart rate, and modestly contributes to agonist-induced
contraction of smooth muscles of the stomach fundus and urinary bladder, and bronchial
constriction of the trachea (Billington and Penn, 2003). In rat neostriatal cholinergic
intemeurons, activation of the M2 receptor results in reduction ofN- and P-type Ca^"^
currents (Yan and Surmeier, 1996) that regulate neurotransmitter release (Dunlap et al.,
1995), potentially through a G-protein py-dependent mechanism (Herlitze et al., 1996).
Postsynaptic cells can be hyperpolarized in response to M2 activation. For example, cells
of the rat nucleus raphe magnus are hyperpolarized by an inwardly rectifying potassium
current in response to M2 activation (Pan and Williams, 1994). The M2 mAChR plays a
key role in the regulation ofnumerous physiological systems that deal with development,
learning and memory, and movement control (Levey, 1996).
1.2 GPCR down-regulation
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A general feature ofmAChRs and other GPCRs is that they are highly regulated
(Koppen and Kaiser, 2003). One highly regulated process is receptor down-regulation,
or the reduction in the total amount of receptor present. Down-regulation can be caused
by a number of factors, including inhibition of gene transcription, mRNA instability,
inhibition ofmRNA translation, or increased protein degradation. The amount of
mAChR present can be altered in response to agonist exposure. Short-term agonist
exposure (seconds to minutes) causes a rapid removal ofmAChR from the cell surface
(Galper et ah, 1982), while agonist exposure for longer periods of time (hours) causes
receptor down-regulation (Klein et ah, 1979; Taylor et ah, 1979; Hunter and Nathanson,
1984). The mechanisms involved in mAChR sequestration and down-regulation are not
clearly defined. Furthermore, few specific receptor domains involved in the regulation of
mAChR number have been identified (Moro et ah, 1993). Previous studies found that the
cytoplasmic tail tyrosine residue of the M2 mAChR is involved in agonist-induced down-
regulation of the receptor (Goldman and Nathanson, 1994).
1.3 GPCR activation and phosphorylation
An array ofprotein kinases are able to phosphorylate mAChRs, including various
GPCR kinases (GRKs), casein kinase la (CKl a), and diacylglycerol-regulated protein
kinase C (PKC) (Haga and Haga, 1990; Kwatra and Hosey, 1986).When an agonist
stimulates a GPCR, GDP is exchanged for GTP on the Ga subunit, leading to dissociation
of the heterotrimer G-protein into Ga and Gpy dimer subunits. The Gpy subimit complex is
prenylated with a geranylgeranyl group at the C terminus ofy and is membrane-bound
(Casey et ah, 1998). In a coordinated process, free Gpy and membrane
4
phosphatidylinositol biphosphate bind to GRK2 or GRK3 at the C-terminal domain,
termed a pleckstrin homology domain (DebBurman et al., 1996; Pitcher et al., 1995).
Interaction of these ligands with the pleckstrin homology domain translocates or targets
the GRK2 to the membrane-bound, agonist-occupied receptor (Daaka et al., 1997).
Phosphorylation occurs on serine and threonine residues located at sites 286-290 and
307-311 in the third intracellular loop and the C-terminus ofmAChRs (see Figure 1).
1.4 Arrestin proteins
After the agonist-occupied GPCR is activated, P-arrestin selectively binds to the
active phosphorylated receptor, covering its cytoplasmic tip and sterically hinders the
interaction of cognate G-protein and receptor (Luttrell and Lefkowitz, 2002; Krupnick et
al., 1997). Mammals have only four arrestin proteins that participate in the regulation of
over 800 different GPCRs (Luttrell and Lefkowitz, 2002; see Table 1).
P-arrestin proteins were originally discovered to “arrest” G-protein mediated cell
signaling events (Benovic et a/.,1987). However, considerable insight has been gained in
understanding the mechanisms by which P-arrestin modulates GPCR function. The
classical physiological functions of the p-arrestins are GPCR desensitization and
sequestration (Kohout et al., 2001). Desensitization is a decrease in the ability ofGPCRs
to initiate signaling cascades, which is caused by exposure to agonist (reviewed in
Bunemaim et al., 1999). Arrestin binding prevents further G-protein activation and often
redirects signaling to other pathways (Vishnivetskiy et al., 2003).
The expression of visual arrestin (arrestin1) and cone arrestin (arrestin 4) is
limited to rod and cone photoreceptors, where they quench the signaling of rhodopsin and
cone opsins, respectively (Yamaki et al., 1987). Visual and cone arrestins have
m2 mAChR
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Figure 1. Schematic diagram of the M2 mAChR. The diagram exaggerates the third
intracellular loop where phosphorylation by serine and threonine kinases occurs at the N-
cluster and C-cluster sites. The A1 and A2 sites are important for P-arrestin mediated
internalization.
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370 *p2, *M2
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(arrestin-2) 410 rhodopsin binding.
phosphorylation
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(arrestin-4)
*p2- P2 adrenergic receptor, * M2- M2 mAChR
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specialized functions as a result of their limited localization in the visual system.
Therefore, the only two non-visual arrestins, arrestin 2 and arrestin 3, also referred to as
P-arrestin 1 and 2, regulate the vastmajority ofGPCRs. Unlike the visual arrestins, p-
arrestin 1 and 2 are ubiquitously expressed in all cell types, albeit in various levels
(Krupnick and Benovic, 1998; Lohse et al, 1990; Attramadal et al., 1992). Analogous to
visual arrestins that desensitize light-activated rhodopsin, the nonvisual arrestins also
participate in processes controlling re-establishment of receptor responsiveness in certain
GPCRs such as the adrenergic receptors (Ferguson et al, 1996; Zhang et al, 1997; Yu et
al, 1993; Pippig et al, 1995). P-arrestins target desensitized receptors for endocytosis
and resensitization by functioning as docking proteins that link receptors to components
of the endocytotic machinery such as p-adaptor Protein 2 (AP-2) and clathrin (Laporte et
al, 1999; Ferguson et al, 1996; Laporte et al, 2000; Goodman et al, 1996). P-arrestins
also regulate the rate at which some GPCRs are dephosphorylated and recycled back to
the plasma membrane through interactions with specific clusters ofphosphorylated
residues in the GPCR carboxy terminus (Oakley et a/., 1997). Over the past several years,
knockout (KO) mice, in which the genes for P-arrestin 1 and 2 have been inactivated by
homologous recombination, have been developed. The mouse embryonic fibroblasts
(MEFs) that were derived from these knockout mice have greatly aided the study of the
physiological and cellular roles of these multifunctional proteins (Kohout et al, 2001).
1.5 Class A and B receptors
There are two distinct classes ofGPCRs, termed class A and B, in which
endocytotic mechanisms are mediated by arrestin molecules. For class A receptors (e.g.,
p2 adrenergic receptor, mu opiod receptor, endothelin type A receptor, dopamine DIA
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receptor, and aib-adrenergic receptor), which recycle rapidly, p-arrestin directs the
receptors to clathrin-coated pits, but does not internalize with them (Oakley et al., 2000).
In contrast, in class B receptors (e.g., angiotensin II type 1A receptor, neurotensin
receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone receptor, and
substance P receptor), which recycle slowly, P-arrestin and its receptor traffic together
from cell membrane to endocytotic vesicles (Oakley el al, 1999). Class A receptors bind
P-arrestin 2 with a higher affinity than p-arrestin 1 and do not interact with visual arrestin
(Gurevich et al., 1995). P-arrestin 2 binds theM2 mAChR with a 1.5 fold greater
affinity than p-arrestin 1 (Gurevich et al., 1995). On the other hand, class B receptors
bind both P-arrestin isoforms with similar high affinities and also interact with the visual
arrestins (Oakley et al., 2000). To date, it is not known whether the M2 mAChR is a
class A or B receptor.
1.6 Ubiquitination
The focus of this study is to elucidate certain aspects of the mechanism mediating
the down-regulation of the M2 mAChR. Previous studies indicate that the ubiquitin-
proteasome system plays important roles in several biological processes (Hershko and
Ciechanover, 1998; Lee and Goldberg, 1998; Pickart, 2001). Ubiquitination is a post-
translational attachment ofubiquitin residues to the lysines of substrate proteins.
Recently, it has been shown that the vasopressin receptor V2 (V2R), a class B receptor, is
ubiquitinated following agonist stimulation (Martin et al., 2003). The researcher
postulates that stimulation ofM2 mAChR leads to short-term or long-term arrestin
ubiquitination. The V2R is ubiquitinated at a single lysine residue (lysine 268) in the
third intracellular loop. This ubiquitination leads the V2R to a rapid degradative pathway
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(Martin et al., 2003). In contrast to polyubiquitination, which leads to proteasomal
degradation, mono-ubiquitination can act as a sorting signal (Pickart, 2001).
Polyubiquitination is the attachment of the first ubiquitin to the substrate lysine followed
by the formation of a polyubiquitin chain on the first ubiquitin (Shenoy and Lefkowitz,
2003). As previously stated, monoubiquitination, which is the attachment of a single
ubiquitin molecule at a single lysine residue, acts as a sorting signal. Previous studies on
the tumor suppressor p53 showed that a p53-ubiquitin fusion protein that mimicked
monoubiquitinated p53 was found to accumulate in the cytoplasm, indicating that
monoubiquitination is critical for p53 trafficking (Li et al., 2003).
Protein ubiquitination usually requires three processes involving the ubiquitin-
activating enzyme (El), ubiquitin-conjugating enzyme (E2) and ubiquitinligase (E3)
(Pickart, 2001). The C-terminus ofubiquitin is initially activated through its high-energy
thioester linkage to a cysteine side chain on the El protein. This reaction requires ATP,
and it proceeds via a covalent AMP-ubiquitin intermediate. The activated ubiquitin on
El is then transferred to cysteine on a set of E2 molecules. The E2-E3 complex attaches
the ubiquitin residue to the substrate protein (see Figure 2). Protein polyubiquitination
provides the recognition signal for 26S proteasome association and leads to proteolysis.
As mentioned earlier, activation of the receptor produces fi’ee G|iy within the
cytosol. Previous studies have shown that Gpy increases the activity of




Figure 2. Diagram depicting the process of ubiquitination and proteasomal degradation.
showed that activation of the PI 3-K leads to androgen receptor (AR) ubiquitination and
degradation via a proteasome-dependent pathway. This same study demonstrated that
MdM2, an E3 ubiquitin ligase, and Akt, a serine/threonine kinase, formed a complex with
AR and induced AR ubiquitination and degradation in a phosphorylation-dependent
manner. The effect ofAkt on AR ubiquitination and degradation was markedly lower in
an MdM2-null cell line compared with the wild-type cell line. This suggests that
phosphorylation-dependent AR ubiquitination and degradation require the involvement of
MdM2 E3 ligase activity and provide further insight into how AR is targeted for
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degradation. Recently, P-arrestin 2 has been shown to interact with MdM2, which
targets p-arrestin 2 for ubiquitination (Shenoy et al., 2001). Therefore, it was
hypothesized that agonist-induced down-regulation ofM2 mAChR is facilitated by the
ubiquitination of p-arrestin.
1. 7 Aim and scope of the study
The experiments that were conducted for this thesis were designed to test the
hypothesis: agonist-induced down-regulation ofM2 mAChR is facilitated by the
ubiquitination of p-arrestin. Three specific aims were addressed:
Aim 1. To determine whether down-regulation ofM2 mAChR is selectively
mediated by either P-arrestin 1 or 2.
Aim 2. To determine whether ubiquitination of p-arrestin 2 enhances down-
regulation ofM2 mAChR.





[^H]-Quinuclidinyl benzilate (QNB; 47 Ci/mmol) was purchased from
Amersham Corp. Dulbecco's modified Eagle's medium (DMEM), F-10 Nutrient mixture,
penicillin/streptomycin, fetal bovine serum, and LipofectAMINE 2000 were purchased
from Life Technologies. The anti-FLAG monoclonal and anti-FLAG polyclonal
antibodies were purchased from Sigma-Aldrich. Ubiquitin antibody Ub P4D1 was from
Santa Cruz Biotechnology. Secondary horseradish peroxidase (HRP)-conjugated
antibodies were purchased from Jackson Laboratory. A purification kit for DNA was
purchased from Qiagen. Protein A agarose beads, carbamylcholine chloride (carbachol),
atropine and all other chemical reagents were purchased from Sigma. Dr. Neil
Nathanson (University ofWashington) kindly provided the porcine FLAG-taggedM2
mAChR construct. TheMEF wild-type, p-arrestin 1 and 2 single knockouts, jS-arrestin
1 and 2 double knockout cells, FLAG-tagged p-arrestin 1 and 2, and YFP-P-arrestin-2-
Ub were kindly provided byDr. Robert Lefkowitz (Duke UniversityMedical Center).
CHO cells stably expressing human M2 mAChR were generously provided by Tom
Boimer.
2.1 Cell culture and transient transfection
Mouse embryonic fibroblasts (MEF) derived from P-arrestin knockout out mice
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and Chinese hamster ovary (CHO) cells were used throughout this study. MEFs were
cultured in DMEM medium supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin. CHO cells were cultured in FIO medium supplemented with
10% serum. MEF as well as CHO cell cultures were kept at 37°C in a humidified 5%
CO2 environment. Transfections were made in 6 well plates with LipofectAMINE 2000
(Invitrogen) according to the manufacturer's instructions. Following 24 hr ofplating,
seeded cells at 80% confluency were transfected using a DNA: LipofectAMINE ratio of
1:2.5. The cells and the transfection mixture were incubated in serum-free DMEM or F-
10 for 5 hr. Experiments were performed 24-48 hr after transfection.
2.2 Saturation binding assay
[^H]-QNB binding to mAChRs in crude membrane homogenates from MEFs was
performed according to Halvorsen and Nathanson (1981) as modified from the method of
Yamamura and Snyder (1974). The final assay mixture contained 100 pi ofmembrane
homogenate and, unless otherwise noted, 0.67 nM [^H]-QNB in a final volume of 1 ml
with 50 mM sodium phosphate, pH 7.4. Incubation with [^H]-QNB was carried out at
room temperature for 90 minutes. The radioligand-binding assay was stopped by the
addition of 5 ml of ice-cold 50 mM sodium phosphate buffer to each assay tube and
placing the tubes on ice. Radiolabeled samples were passed through a Whatman glass
fiber filter (2.5 cm GF/C, presoaked in a 0.1% solution ofBSA in 50 mM sodium
phosphate buffer, pH 7.4). Each assay tube was rinsed 3 times with ice-cold 50 mM
sodium phosphate buffer, pH 7.4, and the GF/C filter was placed in vials to which 4 ml of
scintillation fluid was added. In all experiments, nonspecific binding was determined as
amount of [^H]-QNB binding remaining in the presence of 1 pM of the muscarinic
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antagonist atropine. Activities were expressed as [^H]-QNB bound in Fmol permg
protein. Protein was estimated by the Bradford method, using bovine serum albumin as a
standard.
2.3 Immunoprecipitation
Immunoprecipitations were done as described previously (Santini et al., 2002).
Briefly, CHO cells were transiently transfected with FLAG-tagged |3-arrestin 2. Twenty
four hours following transfection, stimulated and non-stimulated cells were lysed in 100
pi of lysis buffer containing: 1% Triton X, 10% glycerol, 50 mM HEPES (pH 7.5), 10
mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 10 mM N-ethylmaleimide (NEM),
andl pg/ml of protease inhibitors leupeptin, aprotinin, and pepstatin A. Cells were lysed
by sonication. The protein concentration was determined using the Bradford assay
method. Lysates were precleared with Protein A agarose beads for 45 min at 4°C with
rotation, followed by incubating 300 pg ofprecleared protein with 5 pg ofpolyclonal
anti-FLAG antibody at 4°C overnight. The immunocomplex were incubated for 1 hr
with 50 pi Protein-A beads (50% slurry) at 4°C with rotation. After washing, the beads
were resuspended in 50 pi ofLaemmli buffer and boiled for 5-10 min. The
immunocomplex was resolved in a 4-20% gradient gel.
2.4 Immunoblotting
Western blot analysis was performed on extracts of cells cultured in 6-well plates.
Proteins were solubilized in 100 pi of lysis buffer mentioned above. Fifty micrograms of
cell lysates were subjected to 4-20% sodium dodecyl sulfate-polyacrylamide gradient gel
electrophoresis (SDS-PAGE). After transfer, the nitrocellulose membrane was blocked
with 5% powdered nonfat milk, Tris Buffered Saline, and 5% Tween 20 (TTBS) and then
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probed with anti-Ubiquitin monoclonal antibody (Ub P4D1). An additional 50 pg of
cell lysates were subjected to electrophoresis on 4-20% gradient gel. After transfer, the
nitrocellulose membrane was blocked, and probed with a monoclonal anti-FLAG
antibody. Immunoreactive bands were visualized by enhanced chemiluminescence after
adding horseradish conjugate anti-mouse antibody.
2.5 Statistical analysis
Statistical analyses were performed using ANOVA with post hoc
Bonferroni/Dunn test. This test was used because comparisons were made between




3.0 jS-arrestin mediated down-regulation of the M2 mAChR
To determine whether agonist-induced down-regulation of the M2 mAChR is
arrestin dependent, radioligand binding assays were performed with MEF double
knockout cells (KOl/2) transiently expressing FLAG-tagged porcine M2 mAChRs and
FLAG-tagged j8-arrestin 1 or 2. Approximately 24 hr following transfection, cells were
stimulated for 6 hr at 37°C with 1 mM carbachol, amuscarinic agonist. InMEF KOl/2
cells transiently expressing onlyM2 mAChRs, there was no agonist-induced down-
regulation (see Figures 3 and 4). However, inMEF KOl/2 cells transiently expressing jS-
arrestin 1 or 2, agonist-induced down-regulation could be rescued. In MEFs transiently
expressing M2 mAChR and /3-arrestin 1 or 2, agonist-induced down-regulation was 40-
50% (see Figures 3 and 4). These results indicate that down-regulation does not occur in
the absence of jS-arrestins. Furthermore, there does not appear to be any selectivity
among either /3-arrestin isoform in mediating down-regulation. Based on these results,
agonist-induced down-regulation is arrestin dependent.
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Figure 3. Agonist-induced down-regulation ofM2 rnACliR in MEF KOl/2 can be
rescued by transiently expressing P-arrestin 1. 24 hr following transfection, cultures were
stimulated or not with ImM carbachol for 6 hr. Radioligand binding assay was
performed with the membrane permeable muscarinic antagonist [^H]-QNB. Data are
presented as the mean ± standard deviation from 3 independent experiments. Statistical
test was performed using ANOVA with post hoc Bonferroni/Dunn test (asterisk indicates








Agonist - + - +
P-arrestin 2 - - + +
Figure 4. Agonist-induced down-regulation ofM2 mAChR in MEF KOl/2 can be
rescued by transiently expressing P-arrestin 2. 24 hr following transfection, cultures were
stimulated or not with ImM carbachol for 6 hr. Radioligand binding assay was
performed with the membrane permeable muscarinic antagonist [^H]-QNB. Data are
presented as the mean ± standard deviation from 3 independent experiments. Statistical
test was performed using ANOVA with post hoc Bonferroni/Dunn test (asterisk indicates
that p < 0.003).
3.1 Dose and time response of the M2 mAChR.
Dose and time-dependent down-regulation ofM2 mACtiRs was studied to
ascertain whether there was any selectivity between P-arrestin 1 or 2 mediating M2
mAChR down-regulation. In the dose-response experiments, agonist stimulation resulted
in ~28% down-regulation at 10'^ M carbachol, and ~39% down-regulation at 10'^M
carbachol, and ~47% down-regulation at 10'^M carbachol in MEF KO 1 cells (see Figure
5). In MEF KO 2 cells, agonist stimulation produced a similar 28-46% down-regulation
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with concentrations of agonist ranging from 10'^M to 10'^M carbachol (see Figure 5).
Although not significant because ofhigh variability, M2 mAChRs appear to undergo a
dose-dependent down-regulation.
In the time-response experiments, stimulation ofMEF KOI or K02 transiently
expressingM2 mAChRs with agonist demonstrated a time-dependent down-regulation
that was maximal at 6 hr (see Figure 6). Down-regulation of~39 % was observed at 6 hr
of stimulation in MEF KOI, and ~30 % down-regulation occurred at 6 hr in MEF K02
(see Figure 6). These data clearly demonstrated that transiently expressed M2 mAChRs
showed no selectivity for either P-arrestin isoform, and maximal down-regulation was
observed around 6 hr for bothMEF KOI and K02.
3.2 Increases in p-arrestin 2 ubiquitination by stimulation of
M2 mAChR
In order to test the hypothesis that ubiquitination of P-arrestin leads to down-
regulation ofM2 mAChR, experiments were conducted to examine whether P-arrestin 2
undergoes ubiquitination as a result of agonist-induced stimulation of the M2 mAChR.










Figure 5. Dose-dependent down-regulation response ofM2 mAChRs is similar in MEF
KOI and K02 cells. 24 hr following transfection with M2 mAChR, cells were
stimulated with various doses of carbachol for 6 hr. Data are presented as the mean ±
standard deviation from 2 independent experiments performed in duplicate. Statistical
test was performed using ANOVA with post hoc Bonferroni/Duim test (asterisk indicates










Figure 6. M2 mAChR down-regulation responsiveness ofMEF KOI and K02 cells
does not increase after 6 hr of agonist stimulation. 24 hr following transfection withM2
mAChR, cells were stimulated with ImM carbachol for various times. Data are
presented as the mean ± standard deviation fi'om 2 independent experiments performed in
duplicate. Statistical test was performed using ANOVA with post hoc Bonferroni/Dunn
test (asterisk indicates that p < 0.005 for KOI).
The results indicated that p-arrestin is ubiquitinated following agonist stimulation ofM2
mAChR, and there also appeared to be an increase in ubiquitination with increased
agonist time treatment (see Figure 7A). Figure 7B indicates that the relative amount of P-
arrestin in each sample was the same. The intensity of the higher molecular weight bands
increases with time, suggesting that stimulation ofM2 mAChR leads to a stable
ubiquitination pattern of P-arrestin. Interestingly, ubiquitination in the absence of
A.
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IP: Flag p-arrestin 2
IB: Ubiquitin
Transfected - + + + +
1 mM Carbachol - - + + +
Time (min) 0 0 3 15 30
Transfected - +
1 mM Carbachol




Figure 7. Agonist stimulation of the M2 mAChR increased ubiquitination of p-arrestin 2
in CHO cells. CHO cells endogenously expressing M2 mAChRs and overexpressing
FLAG-tagged P-arrestin 2 were stimulated with ImM carbachol for the indicated times at
37° C. Following stimulation, FLAG-tagged P-arrestin 2 was immunoprecipitated (IP) as
described in the methods section. Immunoblot (IB) is a representation of three
independent experiments.
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agonist stimulation was detected, indicating that arrestin is apparently being
ubiquitinated without stimulation by agonist.
3.3 Enhancement of down-regulation of M2 mAChRs by ubiquitination of p-
arrestin.
In order to determine ifubiquitinated P-arrestin enhances M2 mAChR down-
regulation, DNA encoding a chimeric (Yellow fluorescent protein) YFP- P-arrestin-2-Ub
fusion protein was co-transfected with M2 mAChRs in MEF KOl/2 cells. The results
indicated that the presence of the already ubiquitinated form of P-arrestin almost
completely depleted M2 mAChRs, even in the absence of agonist (see Figure 8). In the
absence of arrestin, there was no agonist-induced down-regulation. Addition of P-
arrestin 2 resulted in ~50 % down-regulation, while addition of a permanentlymono-
ubiquitinated p-arrestin 2 resulted in almost complete depletion ofM2 mAChR with
~85% down-regulation in the absence of agonist. In the presence of agonist, ~95%
down-regulation occurred in the sample containing the permanently mono-ubiquitinated










Agonist - + - + .+
P-arrestin 2 - - + +
P-arrestin 2-Ub - - - . + +
Figure 8. P-arrestin 2-Ub enhances agonist-induced down-regulation ofM2 mAChR in
MEF KOl/2 cells. MEF KOl/2 cells were transfected with M2 mAChR, or co¬
transfected with M2 mAChR and FLAG-tagged P-arrestin 2 or chimeric YFP- P-arrestin-
2-Ub fusion protein. 24 hr after transfection, cells were stimulated or not with ImM
carbachol for 6 hr. Agonist induced down-regulation was determined as described in the
methods section. Data are presented as the mean ± standard deviation from 3
independent experiments. Statistical test was performed using ANOVA with post hoc
Bonferroni/Dunn test (asterisk indicates that p < 0.003).
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3.4 Attenuation ofM2 mAChR down-regulation by proteasomal inhibition.
The last aim was to determine ifdown-regulation could be inhibited by using a
proteasomal inhibitor (lactacystin). Twenty four hours following transfection, cultures
were pretreated with 10 pM lactacystin prior to stimulation or not with ImM Carbachol
at 37°C. Agonist-induced down-regulation was determined 2 and 4 hr following
stimulation. Lactacystin pretreatment attenuated down-regulation to ~7% from the ~32%
down-regulation observed in untreated cells (see Figure 9). However, lactacystin did not
prevent agonist-induced down-regulation at 4 hr of stimulation, with -30% and -37%
down-regulation observed in lactacystin treated and untreated cells, respectively (see




















■ No Lactacystin Pretreatment
□ 20 min Lactacystin Pretreatment
2 hr Stimulation with 1 mM Carbachol
Figure 9. Treatment with lactacystin attenuates agonist-induced down-regulation
in MEF KOI cells after 2 hr of stimulation. MEF KOI cells were transfected
with M2 mAChR and treated or not with 10 fxM lactacystin for 20 min. prior to
stimulation or not with ImM carbachol for 2 hr. Agonist induced down-
regulation was determined as described in the methods section. Data are
presented as the mean ± standard deviation from 3 independent experiments.
Statistical test was performed using ANOVA with post hoc Bonferroni/Dunn test































■ No Lac Pretreatment
□ Lac Pretreatment
4 hr stimulation 1 mM Carbachol
Figure 10. Treatment with lactacystin does not attenuate agonist-induced down-
regulation in MEF KOI cells after 4 hr of stimulation. MEF KOI cells were
transfected with M2 mAChR and treated or not with 10 laM lactacystin for 20
min. prior to stimulation or not with ImM carbachol for 4 hr. Agonist induced
down-regulation was determined as described in the methods section. Data are
presented as the mean ± standard error from 3 independent experiments.
Statistical test was performed using ANOVA with post hoc Bonferroni/Dunn test.
CHAPTER 4
DISCUSSION
Short term agonist exposure (seconds to minutes) causes a rapid removal of
mAChR from the cell surface (Galper et al., 1982), while agonist exposure for longer
periods of time (hours) causes receptor down-regulation (Klein et al., 1979; Taylor et al.,
1979; Hunter and Nathanson, 1984). Previous studies have indicated that internalization
ofM2 mAChR was mediated via jS-airestin-independent and dependent pathways (Pals-
Rylaarsdam et al, 1997). The data showed thatM2 mAChRs undergo no agonist-induced
down-regulation in the absence of /J-arrestin. Furthermore, based on the experiments
designed to determine whether /3-arrestin 1 or 2 played differential roles in mediating
down-regulation of theM2 mAChR, it was found that /S-arrestin 1 and 2 were both able
to mediate down-regulation ofM2 mAChR.
In the present study, the investigator examined whether agonist-induced down-
regulation ofM2 mAChR was mediated by ubiquitination of |8-arrestin. Previous studies
on the ^2 adrenergic receptor showed that /3-arrestin undergoes agonist-dependent
ubiquitination (Shenoy and Lefkowitz, 2003). Furthermore, ubiquitination of the ^2
adrenergic receptor, which requires /S-arrestin as an adaptor to recruit ubiquitination
enzymes, is necessary for targeting of the receptor to the lysosomes for degradation. In
this study, it was shown that stimulation ofM2 mAChR causes an increase in
ubiquitination of /8-arrestin 2.
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Ubiquitination is used by all eukaryotic organisms to control the stability,
function, and intracellular localization of a wide variety ofproteins (Horak, 2003).
Protein ubiquitination, in particular polyubiquitination, is used to mark proteins for
degradation by cytosolic proteasomes. In addition, protein ubiquitination promotes the
internalization ofcertain plasma membrane proteins through the endocytotic pathway,
followed by their degradation in the vacuole in yeast and the lysosome in mammalian
systems (Horak, 2003). Recent studies ofmembrane proteins both in yeast and
mammalian cells suggest that the role of ubiquitin may not be limited to functioning as an
internalization signal. It also may be required for modification of some component of the
endocytotic machinery, and for cargo protein sorting at the late endosome and the Golgi
apparatus (Horak, 2003). In this study, experiments were designed to determine whether
agonist-induced down-regulation ofM2 rnACliR is mediated through ubiquitination of P-
arrestin.
In this investigation, down-regulation of the M2 mAChR was attenuated after 2
hours of stimulation with agonist by pre-treating cultures with a proteasomal inhibitor,
lactacystin. Studies have shown that lactacystin has been reported to block
internalization and/or endosomal sorting. Internalization ofgrowth hormone receptor
(GHR) is blocked by lactacystin (van Kerkhof et al., 2000). However, another cytokine
receptor, interleukin-2, is able to internalize with proteasomal inhibition, but is then
unable to sort to late endosomes for degradation (Rocca et al, 2001). This raises several
new questions because it suggests that the M2 mAChR may imdergo down-regulation by
degradation pathways other than the lysosome, such as the proteasome, or that lactacystin
is preventing internalization of the receptor and/or sorting to late endosomes. Hammond
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and co-workers (2003) showed that proteasomal activity is required forMet receptor
(MetR) degradation after stimulation with hepatocyte growth factor (HGF). Inhibition of
proteasomal activitywith lactacystin blocked endocytotic trafficking ofMetR in which
the receptor failed to reach late endosomes/lysosomes, where degradation takes place.
Studies have shown that the MetR is ubiquitinated after stimulation (Jeffers et al., 1997).
Hammond and co-workers (2003) proposed that proteasome inhibition by lactacystin may
affect MetR trafficking indirectly, particularly, interfering with receptor ubiquitination by
preventing the recycling of cellular ubiquitin, and consequently reducing cellular levels
of free ubiquitin. Therefore, it is possible that lactacystin was able to attenuate down-
regulation of the M2 mAChR by indirectly interfering with the ubiquitination of P-
arrestin.
Recently, it has been demonstrated that inhibiting p-arrestin ubiquitination, either
by use of a dominant negative form of its E3 ligase MdM2 or by using MdM2-null cell
lines, did not inhibit degradation of the P2 adrenergic receptor (Shenoy and Lefkowitz
2003). Nonetheless, in the same study, an ubiquitinated P-arrestin 2 was observed to be
associated with not only more robust P2 adrenergic receptor sequestration, but also
increased receptor degradation with agonist stimulation. This is consistent with the
findings in this study, where it became evident that in even in the absence of agonist, the
M2 mAChR was significantly degraded in the presence of the YFP- P-arrestin-2-Ub
fusion protein. This may be attributed to the fact that ubiquitinated forms of P-arrestin
serve as a sorting signal for lysosomal degradation (Katzmann et al., 2001 ; Lloyd et al.,
2002 ; Polo et al., 2002).
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Recent studies have shown that the V2R is ubiquitinated following agonist
stimulation (Martin et ah, 2003). V2R ubiquitination is not observed in MEF KOl/2.
However, V2R ubiquitination can be restored by introducing P-arrestin 2, indicating that
P-arrestin 2 is required for the ubiquitination ofV2R. Following mutations of a lysine
residue (at site 268) to arginine, which prevents ubiquitination, a mutant V2R (K268R)
still activates Gs and internalizeswith similar kinetics as the wild type receptor.
Unstimulatedwild type and K268R mutant receptors degrade at similar rates and have
comparable half-lives; however, following agonist stimulation, the rate of receptor
degradation for the wild type is enhanced, whereas that of the mutant is onlyminimally
affected. Therefore, ubiquitination ofV2R is essential for mediating agonist-induced
down-regulation. Furthermore, P-arrestin is necessary for facilitating down-regulation.
These data suggest that V2R levels are regulated through at least two processes. In the
absence ofagonist stimulation, a slow degradative pathway operates that is independent
of receptor ubiquitination. However, receptor stimulation leads to rapid P-arrestin 2-
dependent ubiquitinationof the receptor and increased degradation. The findings
demonstrated that M2 mAChRs do not undergo agonist-induced down-regulation in MEF
KOl/2. Unlike the V2R, this study found no evidence indicating that the M2 mAChR
itself is ubiquitinated upon stimulation with agonist.
The vast majority of the experiments were conducted in systems that were
artificial and not necessarily representative ofnaturally occurring biological systems.
Therefore, one might argue that the implications of the studymay not apply in vivo.
Even though the MEF cells that were used do not endogenously express M2 mAChRs,
this cell line has near isogenic derivatives that express one (KOI and K02) or no
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(KOl/2) P-arrestin. This was done to efficiently study the mechanism that leads to
degradation of the M2 mAChR. The use of the knock-out cells was effective in
determining if either P-arrestin isoform played differential roles in mediating agonist-
induced down-regulation ofM2 mAChRs, and also ifdown-regulation occurred in the
absence of arrestin. Based on the results, it was concluded that there was no significant
difference in the manner in which p-arrestin 1 or 2 regulated down-regulation ofM2
mAChRs, and that down-regulation ofM2 mAChRs is arrestin-dependent.
Activation of the GPCRs produces free Gpy within the cytosol (Casey et al.,
1998). Previous studies have shown that Gpy increases the activity ofPI 3-K (Sellers et
al., 2000). Lin et al. showed that activation of the PI 3-K leads to AR ubiquitination and
degradation via a proteasome-dependent pathway (2002). This same study demonstrated
thatMdM2, a RING finger-dependent E3 ubiquitin ligase, and a serine/threonine kinase,
Akt, formed a complex with AR and induced AR ubiquitination and degradation in a
phosphorylation-dependent manner. The effect ofAkt on AR ubiquitination and
subsequent degradation was markedly lower in an MdM2-null cell line compared with the
wild-type cell line. This suggests that phosphorylation-dependentAR ubiquitination and
degradation require the involvement ofMdM2 E3 ubiquitin ligase activity and provides
further insight into how AR is targeted for degradation. Recently, it has been shown that
MdM2 regulates the ubiquitination ofP-arrestin 2 (Shenoy et al, 2001). Furthermore,
Wang and co-workers (2003) showed that binding ofMdM2 to P-arrestin 2 was
significantly enhanced by stimulation ofGPCRs, and that activation ofGPCRs led to the
formation ofa ternary complex ofMdM2, p-arrestin 2, and GPCR, thereby recruiting
MdM2 to GPCRs at the plasma membrane.
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The proposed pathway that leads to degradation of the M2 mAChR involves
the activation ofPI 3-K due to the production of free Gpy, which occurs when the receptor
is activated. This in turn would lead to an increase in the activity ofE3 Ubiquitin ligase,
which then attaches the ubiquitin residues to the P-arrestin that M2 mAChRs recruit upon
stimulation with agonist. It was hypothesized that it is this ubiquitinated form of arrestin
that serves as a sorting signal for the receptor-arrestin complex to be shunted over to the







Figure 11. Proposed pathway that leads to degradation of the M2 rnACliR.
4.0 Conclusion
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In conclusion, it was demonstrated that agonist-induced down-regulation of the
M2 mAChR is arrestin-dependent, and is not differentially mediated by either P-arrestin 1
or 2. The data indicates that stimulation of the M2 mAChR causes an increase in the
ubiquitination of P-arrestin 2. Furthermore, expression of the chimeric ubiquitinated
form of P-arrestin 2 (YFP- p-arrestin 2-Ub) enhances down-regulation ofM2 mAChRs in
stimulated as well as non-stimulated MEF cultures. The findings demonstrated that
proteasomal inhibition attenuates down-regulation of the receptor, suggesting that
proteasomal inhibition may either block sorting to the late endosomes or ubiquitination of
p-arrestin.
4.1 Recommendations
Future studies should address whetherM2 mAChRs undergo ubiquitination
following agonist stimulation, and ifproteasomal inhibition blocks internalization and/or
late endosomal/lysosomal sorting. Furthermore, recognition motifs within the early
endosome that are required for lysosomal sorting should be fiirther investigated, along
with the governing mechanisms that regulate the receptor’s fate once it has entered the
late endosomal compartment.
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